Bispecific antibodies for non-Hodgkin lymphoma
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, reflects on the use of bispecific antibodies in the treatment of non-Hodgkins lymphoma, including glofitamab and...
View ArticleCAR-T and antibody developments: aggressive lymphomas
Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, discusses novel developments in cellular and bispecific antibody therapies for aggressive lymphomas. Specifically discussed is AUTO3,...
View ArticleEmerging lymphoma therapies: bispecific antibodies and CAR T-cells
Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Melbourne, Australia, shares his thoughts on emerging therapies for lymphomas that were presented at ASH 2020. Bispecific antibodies and CAR T-cell...
View ArticleThe Lymphoma Sessions: highlights from ASH 2020
Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for lymphoma are not yet well-characterized and treatment depends on the type of...
View ArticleThe Lymphoma Sessions: ASH 2020 highlights
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific monoclonal antibodies, there is hope for a wider demographic of patients....
View ArticleUpdated efficacy data on glofitamab step-up dosing in NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, talks on updated data from the step-up dosing cohort of the NP30179 trial (NCT03075696), an ongoing multicenter, Phase I...
View ArticleNovel CD20/CD3 bispecific antibodies in NHL
Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies have demonstrated promising clinical...
View ArticleEHA 2021: antibody therapies for NHL
Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research...
View ArticleGlofitamab and obinutuzumab in r/r MCL
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses preliminary data from the Phase I/II trial (NCT03075696) of glofitamab, a CD20xCD3 T-cell engaging...
View ArticleGlofitamab step-up dosing in R/R MCL
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, reports preliminary data from the Phase I/II trial (NP30179; NCT03075696) in patients with relapsed/refractory (R/R) mantle cell lymphoma who...
View ArticleLymphoma highlights from ASH 2021
Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, comments on his highlights in the field of lymphoma presented at ASH 2021, including the Phase III POLARIX trial (NCT03274492) of...
View ArticlePreliminary results from NP40126: Glofitamab and R-CHOP in NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the ongoing, Phase I NP40126 trial (NCT03467373) of glofitamab, a CD20xCD3 T-cell-engaging bispecific...
View ArticleNP30179: Glofitamab monotherapy in R/R NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides updates from the Phase I/II NP30179 trial (NCT03075696) of single-agent glofitamab, a CD20xCD3 T-cell-engaging...
View ArticleGlofitamab and polatuzumab vedotin in DLBCL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents findings from the open-label, Phase Ib/II trial (NCT03533283) trial of glofitamab, a CD20xCD3 T-cell-engaging...
View ArticleSafety and efficacy of plamotamab in the treatment of non-Hodgkin lymphoma...
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses some findings from a Phase I trial investigating the safety and efficacy of plamotamab, an anti-CD20 anti-CD3 bispecific antibody,...
View ArticleClik here to view.
Current treatment options and emerging strategies in MCL
Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, provides an overview of the current treatment paradigm in mantle cell lymphoma (MCL) and outlines emerging therapeutic strategies...
View ArticleAn insight into how bispecifics are changing the lymphoma treatment landscape
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into how bispecifics are changing the lymphoma treatment landscape, highlighting the promise of agents including...
View ArticlePhase II study of glofitamab in patients with R/R LBCL
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the design and results of the pivotal Phase II trial evaluating glofitamab in patients...
View ArticleBispecifics in NHL: epcoritamab and glofitamab
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some insights into the promise of bispecific antibodies for the treatment of non-Hodgkin lymphoma, drawing focus on the promising results...
View ArticleUpdates on glofitamab in MCL
In this video, Tycel Phillips, MD, City of Hope, Duarte, CA, highlights the potential role of glofitamab in the treatment of mantle cell lymphoma (MCL), emphasizing the need for longer follow-up data...
View Article